Genomica
This article was originally published in The Gray Sheet
Executive Summary
Boulder, Colo.-based genomics software developer prices initial public offering of 6.4 mil. shares at $19 each, grossing $122.4 mil. "Our management has broad discretion to allocate the proceeds of the offering," the firm's S-1 prospectus states. CIBC World Markets acted as lead manager for the offering. Dain Rauscher Wessels and Prudential Vector Healthcare Group acted as co-managers. The underwriters have a 30-day over-allotment option to purchase up to 966,000 additional shares. The stock will trade on Nasdaq under the ticker symbol "GNOM"
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.